Laboratorio Reig Jofre, S.A. (RJF.MC) | Investment Case

1. Company Snapshot

1.a. Company Description

Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements.The company offers prescription medicines, OTCs, medical devices, and cosmetics.Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Forté Pharma brand.

The company also provides CDMO and CMO services.It sells its products directly in 7 countries and through business partners in approximately 70 countries.The company was founded in 1929 and is based in Sant Joan Despí, Spain.

Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.

Show Full description

1.b. Last Insights on RJF

Have nothing to say about that one ...

1.c. Company Highlights

Last Price	2.8
Change Percentage	1.82%
Open	2.75
Previous Close	2.75
Market Cap ( Millions)	228
Volume	46119
Year High	3.4
Year Low	2.46
M A 50	2.89
M A 200	2.9

FCF Yield	0.00%
Dividend Yield	1.75%
ROE	4.12%
Debt / Equity	30.99%
Net Debt / EBIDTA	156.03%
Price To Book	1.05
Price Earnings Ratio	25.73
Price To FCF	0
Price To sales	0.55
EV / EBITDA	7.49

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.38%)

6. Segments

Pharmaceutical Services

Expected Growth: 6%

Laboratorio Reig Jofre's Pharmaceutical Services segment growth of 6% is driven by increasing demand for specialty drugs, expansion into new markets, and strategic partnerships. Additionally, investments in digital health technologies and a strong pipeline of innovative products contribute to the segment's growth.

Nutritional Supplements

Expected Growth: 8%

Strong demand for health and wellness products, increasing awareness of preventive healthcare, and rising disposable income drive growth in Nutritional Supplements from Laboratorio Reig Jofre, S.A. Additionally, expanding distribution channels, innovative product offerings, and strategic marketing efforts contribute to an 8% growth rate.

7. Detailed Products

Vaccines

Laboratorio Reig Jofre, S.A. develops and manufactures vaccines for various diseases, including influenza, pertussis, and others.

Biosimilars

The company offers a range of biosimilar products, including filgrastim, pegfilgrastim, and rituximab, for the treatment of cancer and autoimmune disorders.

Plasma Derivatives

Laboratorio Reig Jofre, S.A. manufactures plasma-derived products, including clotting factors, immunoglobulins, and albumin, for the treatment of bleeding disorders and immunodeficiencies.

Critical Care

The company offers a range of critical care products, including anesthetics, analgesics, and sedatives, for use in intensive care units and operating rooms.

Diagnostic Reagents

Laboratorio Reig Jofre, S.A. develops and manufactures diagnostic reagents for the detection of various diseases, including infectious diseases and cancer.

8. Laboratorio Reig Jofre, S.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Laboratorio Reig Jofre, S.A. faces moderate threat from substitutes due to the presence of alternative pharmaceutical products in the market.

Bargaining Power Of Customers

The bargaining power of customers is low due to the specialized nature of Laboratorio Reig Jofre, S.A.'s products, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate due to the presence of multiple suppliers in the market, but Laboratorio Reig Jofre, S.A.'s large scale of operations gives it some negotiating power.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry in the pharmaceutical industry, including regulatory hurdles and high research and development costs.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of several established players in the pharmaceutical industry, leading to intense competition for market share.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	20.02%
Debt Cost	3.95%
Equity Weight	79.98%
Equity Cost	8.34%
WACC	7.46%
Leverage	25.03%

11. Quality Control: Laboratorio Reig Jofre, S.A. passed 5 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

PharmaSGP Holding

A-Score: 5.5/10

Value: 3.9

Growth: 6.6

Quality: 9.0

Yield: 2.5

Momentum: 4.0

Volatility: 7.0

1-Year Total Return ->

Reig Jofre

A-Score: 5.3/10

Value: 6.8

Growth: 7.9

Quality: 5.1

Yield: 1.9

Momentum: 4.0

Volatility: 6.3

1-Year Total Return ->

Vetoquinol

A-Score: 4.5/10

Value: 5.6

Growth: 4.8

Quality: 7.0

Yield: 1.2

Momentum: 3.0

Volatility: 5.7

1-Year Total Return ->

Boiron

A-Score: 4.5/10

Value: 5.7

Growth: 2.1

Quality: 6.2

Yield: 8.8

Momentum: 1.0

Volatility: 3.0

1-Year Total Return ->

Swedencare

A-Score: 3.5/10

Value: 3.1

Growth: 8.9

Quality: 4.7

Yield: 0.6

Momentum: 2.0

Volatility: 1.3

1-Year Total Return ->

PolyPeptide

A-Score: 2.3/10

Value: 3.6

Growth: 4.0

Quality: 2.5

Yield: 0.0

Momentum: 2.5

Volatility: 1.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

14.26%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

7.46%

Laboratorio Reig Jofre, S.A. - ES0165359029

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on RJF

Have nothing to say about that one ...

1.c. Company Highlights

Medium Volatility

Fairly Valued

Average Growth

Stable Momentum

Average Yield

Cheaper

Average Quality

Less Volatile

Higher Growth

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.38%)

6. Segments

Pharmaceutical Services

Expected Growth: 6%

Nutritional Supplements

Expected Growth: 8%

7. Detailed Products

Vaccines

Biosimilars

Plasma Derivatives

Critical Care

Diagnostic Reagents

8. Laboratorio Reig Jofre, S.A.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Laboratorio Reig Jofre, S.A. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.8$

Current Price

2.8$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA